Menopause hormone therapy can relieve symptoms that interfere with sleep, work, sex, and everyday comfort. Choosing treatment begins with the symptoms you want to improve, whether you have a uterus, your medical history, and where you are in the menopause transition. This guide explains what HRT can do, how the main options differ, and what a useful treatment conversation should cover. Here, HRT means hormone therapy for perimenopause and menopause; other uses of hormone treatment require different evaluations.
Start with a specific treatment goal
A useful goal describes daily life: fewer night sweats, less disruption during meetings, or more comfortable intimacy. “Balance my hormones” is harder to measure and does not establish which treatment is appropriate. Before a consultation, record the symptoms that bother you most, when they began, and how often they interfere with activities. Include changes in bleeding, sleep, mood, vaginal comfort, and urinary symptoms.
Estrogen changes can contribute to several of these experiences, but menopause does not explain every new symptom. Persistent fatigue, palpitations, or low mood may need evaluation for other conditions. A clinician can address menopause symptoms while also considering thyroid disease, anemia, sleep disorders, medication effects, or other explanations suggested by your history.
What hormone therapy treats well
Systemic hormone therapy is the most effective treatment for bothersome hot flashes and night sweats. It also helps prevent bone loss while it is being used. Vaginal estrogen can treat local symptoms such as dryness and discomfort, with the choice of product depending on the symptoms and medical context. These established uses are different from claims that hormones universally reverse aging or restore youthful performance. The Menopause Society’s position statement describes the benefits, limitations, and circumstances that change the decision.
Sleep may improve when night sweats improve. That does not mean HRT treats every cause of insomnia. Similarly, relief of vaginal pain can improve sexual comfort without guaranteeing a change in desire. Setting symptom-specific goals makes later follow-up more informative.
Systemic and local treatments have different jobs
“Systemic” means the medicine is intended to act throughout the body. Estrogen pills, patches, gels, and sprays are examples, although available products and instructions vary. Low-dose vaginal estrogen is intended primarily for vaginal and nearby urinary tissues. It is often considered when those symptoms are the main problem and whole-body treatment is unnecessary.
The route alone does not always tell you the treatment’s reach. Some vaginal rings deliver systemic estrogen, while others are low-dose local products. A prescription’s exact name and dose therefore matter more than the word “vaginal.” Someone already using systemic HRT may still need separate treatment for persistent vaginal symptoms. Our local versus systemic HRT guide explains this distinction in more detail.
Why having a uterus changes the prescription
Systemic estrogen can stimulate the uterine lining, also called the endometrium. For someone with a uterus, treatment generally needs a progestogen to protect that lining. Progesterone is one type of progestogen; synthetic progestins are another. After a hysterectomy, estrogen alone is often an option, although the reason for surgery and other medical history can affect the plan. ACOG’s hormone therapy overview explains the basic distinction.
There are specific alternatives, including an approved estrogen combination containing bazedoxifene that provides endometrial protection without a progestogen. Low-dose vaginal estrogen is another distinct situation and generally does not require routine progestogen use. These exceptions should be identified by the prescriber, not inferred from a product’s marketing language.
Perimenopause does not require waiting for the last period
Symptoms can become troublesome while periods are still occurring. A clinician may consider treatment during perimenopause after reviewing bleeding, pregnancy possibility, contraception, and medical history. Waiting for twelve months without a period is not a universal prerequisite for symptom care.
Hormone therapy is not contraception. If pregnancy is possible, you need a separate discussion about preventing it. Hormonal contraception can also change bleeding patterns and complicate the interpretation of hormone tests. Bring the name of any pill, implant, injection, or intrauterine device you use. The perimenopause article covers these overlapping decisions, including why irregular cycles should not automatically be dismissed as a normal transition.
Age and timing inform the benefit-risk discussion
For people without contraindications, the benefit-risk balance is generally more favorable when systemic therapy starts before age 60 or within ten years of menopause onset. Starting later can involve greater absolute risks of cardiovascular disease, stroke, blood clots, and dementia. These are population-level patterns used to guide an individual discussion, not a guarantee based on a birthday. The 2022 position statement also emphasizes reassessment as treatment continues.
Earlier menopause or surgical loss of ovarian function raises different questions from starting HRT many years after natural menopause. Tell the clinician when your periods changed and whether either ovary was removed. A hysterectomy by itself does not necessarily mean both ovaries were removed or that menopause began on the surgery date.
Medical history can change the available choices
Important history includes breast or endometrial cancer, unexplained vaginal bleeding, blood clots, stroke, heart attack, liver disease, and relevant family history. Current medicines, smoking, blood pressure, and migraine history also belong in the discussion. Some conditions make systemic HRT inappropriate or require specialist input; local treatment may involve a different assessment.
Avoid using a friend’s prescription as a template. Two people with similar hot flashes may need different routes or may choose a nonhormonal treatment. The clinician should explain which part of your history affects the recommendation and whether more information is needed before prescribing. Our HRT risks and benefits guide separates route, timing, and personal history rather than treating HRT as one uniform exposure.
What the recent FDA labeling changes mean
In November 2025, the FDA requested changes to menopausal hormone therapy labeling. In February 2026, it approved updated labeling for an initial six products. The changes removed certain cardiovascular, breast cancer, and probable dementia statements from boxed warnings; the endometrial cancer boxed warning for systemic estrogen-alone products remains. Relevant risk information can still appear elsewhere in prescribing information. The FDA’s February 2026 announcement describes the initial approvals.
A revised boxed warning does not make every formulation interchangeable or appropriate for everyone. It also does not establish hormone therapy as a general longevity treatment. Decisions still depend on the indication, the current label for the exact medicine, and individual benefits and risks. Headlines are a starting point for discussion, not prescribing instructions.
Testing is guided by the clinical question
In otherwise healthy people age 45 or older with typical symptoms, menopause is usually identified from symptoms and menstrual history rather than a broad hormone panel. Levels fluctuate during perimenopause, so a single result may provide a poor picture of the transition. Testing can be useful in selected younger patients or when the diagnosis is uncertain. NICE’s menopause recommendations explain these distinctions.
Other tests may answer different questions, such as whether fatigue reflects anemia or whether a medical condition affects treatment safety. Ask what each proposed test would change. Repeated saliva panels marketed as a way to find an exact hormone balance are not an established basis for individualized HRT dosing. Treatment response includes symptoms and tolerability, not simply a laboratory number.
Build follow-up into the initial plan
Before starting, agree on how to use the medicine, what to do after a missed dose, and when to report side effects. Product instructions differ, so obtain directions for your actual prescription. Keep a short symptom record that you can compare with the baseline rather than trying to remember several months at once.
NICE recommends a review at about three months and annually thereafter, with earlier assessment for problems. That is a useful framework, not a reason to wait when something concerning occurs. Discuss new, heavy, persistent, or unexpected bleeding promptly. Postmenopausal bleeding needs evaluation; it should not automatically be attributed to HRT. Our monitoring guide explains the questions to bring to follow-up.
Consider alternatives and the broader care plan
If hormone therapy is unsuitable or unwanted, treatment does not end there. Nonhormonal prescription options and menopause-specific behavioral approaches may help hot flashes or sleep, depending on the problem. Vaginal moisturizers and lubricants can help comfort, while persistent symptoms may need prescription treatment. Ask for an option matched to the symptom rather than a supplement bundle promising comprehensive hormone balance.
Movement, adequate nutrition, sleep care, and routine screening remain relevant whether or not you choose HRT. Hormone therapy should not replace an osteoporosis evaluation, cardiovascular risk management, or assessment of persistent depression. It is also not generally prescribed solely to prevent chronic disease in asymptomatic postmenopausal people, a distinct question addressed by the USPSTF recommendation.
Leave the consultation with a clear decision
A useful visit ends with a defined next step: a prescription and review plan, additional evaluation, a nonhormonal option, or time to consider preferences. You should understand the intended benefit, the main risks that matter for you, and how the clinician will judge whether treatment is helping.
Bring your symptom record, medication list, surgical history, and questions about contraception or bleeding. Ask who handles concerns between appointments and whether the plan changes if vaginal symptoms persist despite improved hot flashes. The first HRT consultation guide provides a practical way to prepare. A successful decision is one that fits your health history and goals and remains open to revision as those change.
Explore the complete series
- HRT During Perimenopause: Symptoms, Cycles, and Treatment Decisions
- Estrogen and Progesterone in HRT: Why the Combination Matters
- Estrogen Patch vs. Pill: Comparing Menopause HRT Routes
- Vaginal Estrogen vs. Systemic HRT: Different Symptoms, Different Treatments
- HRT Risks and Benefits: Age, Timing, and Personal Medical History
- HRT and Weight: Menopause, Body Composition, and Realistic Expectations
- HRT, Hot Flashes, and Sleep: What Improvement Can Look Like
- HRT Testing and Follow-Up: Symptoms, Bleeding, and Laboratory Questions
- Before Starting HRT: A Practical Guide to the First Consultation
- Menopausal skin care and changing skin needs
- Estriol face cream versus menopause hormone therapy
Educational information. Individual treatment selection, prescription directions, and follow-up belong with the treating clinician. Linked guidance and source versions checked September 15, 2026. Medication instructions and evidence can differ by formulation and clinical use. Photographs are illustrative and do not show treatment outcomes.
